Atlas Trials

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Clinical trial NCT04739800 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04739800
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Fallopian Tube Clear Cell AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Fallopian Tube Mucinous AdenocarcinomaRecurrent Fallopian Tube Transitional Cell CarcinomaRecurrent Fallopian Tube Undifferentiated CarcinomaRecurrent Low Grade Fallopian Tube Serous Adenocarcinoma
Start date
2021-06-10
Primary completion
2023-01-26
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.